Answers are grounded in this paper and cite their sources.
The combination of defactinib, pembrolizumab, and gemcitabine was well-tolerated and safe, had promising preliminary efficacy, and showed biomarker activity in infiltrative T lymphocytes. Efficacy of this strategy may require incorporation of more potent chemotherapy in future studies.
No takes yet. Share an insight, caveat, or question.
Wang‐Gillam et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: